GO:2000502 negative regulation of natural killer cell chemotaxis: Immune Evasion Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000502 describes any process that stops, prevents or reduces the frequency, rate or extent of natural killer (NK) cell chemotaxis, the directed migration of NK cells along chemical gradients.
• NK cell chemotaxis is primarily driven by chemokines such as CXCL10 and CXCL14, which bind receptors on NK cells and guide them toward tumors or sites of inflammation.
• Tumors can actively suppress NK cell recruitment by downregulating chemokines or by recruiting regulatory T cells that alter the chemokine milieu, thereby evading immune attack.
• IL-1R8 expression in diffuse large B-cell lymphoma regulates NK cell recruitment and influences patient prognosis, highlighting the clinical relevance of this process.
• Genes such as LMO7, granulysin, and collagen type VI alpha 6 chain have been implicated in modulating NK cell chemotaxis or related immune evasion mechanisms.
• Experimental approaches including CRISPR knockout, knock-in, overexpression, and chemotaxis assays are essential to dissect the molecular players in this regulatory process.
Description
Natural killer (NK) cells are innate lymphoid cells critical for immune surveillance against tumors and infections. Their ability to reach target sites depends on chemotaxis, the directed migration along chemokine gradients. GO:2000502, negative regulation of natural killer cell chemotaxis, refers to any process that stops, prevents or reduces the frequency, rate or extent of NK cell chemotaxis. This regulatory mechanism is crucial for understanding how tumors evade immune responses and how inflammatory diseases may be controlled. Recent studies have shown that tumors can secrete factors or modulate chemokine expression to limit NK cell infiltration, thereby promoting immune evasion. For example, in pancreatic ductal adenocarcinoma, LMO7 drives immune evasion through regulatory T cell differentiation and chemotaxis, indirectly affecting NK cell recruitment. Similarly, human papillomavirus downregulates CXCL14, a chemokine that attracts NK cells, to suppress antitumor immunity. These findings underscore the importance of negative regulation of NK cell chemotaxis in cancer progression and therapy. Researchers studying this process aim to identify molecular targets that can restore NK cell migration and enhance immunotherapy efficacy. Understanding the genes and signaling pathways involved is essential for developing novel therapeutic strategies.
negative regulation of natural killer cell chemotaxis At A Glance
| GO ID | GO:2000502 |
|---|---|
| GO term | negative regulation of natural killer cell chemotaxis |
| Ontology | biological_process |
| Synonym | None |
| Major function | Inhibition or reduction of NK cell migration along chemokine gradients |
| Related processes | Chemotaxis, immune evasion, tumor microenvironment remodeling |
| Key chemokines | CXCL10, CXCL14 |
| Associated genes | LMO7, GNLY, COL6A6, IL1R8 |
| Disease relevance | Cancer, viral infections, inflammatory disorders |
What Is GO:2000502?
According to the Gene Ontology, GO:2000502 is defined as any process that stops, prevents or reduces the frequency, rate or extent of natural killer cell chemotaxis. In other words, it encompasses biological mechanisms that inhibit or dampen the directed movement of NK cells toward chemical signals, such as chemokines. This regulation can occur at multiple levels, including altered chemokine production, receptor desensitization, or interference with intracellular signaling pathways that control cell migration.
Why Is negative regulation of natural killer cell chemotaxis Important in Cell Biology?
Negative regulation of NK cell chemotaxis is a critical mechanism by which tumors and pathogens evade immune destruction. By preventing NK cells from reaching target sites, cancers can escape innate immune surveillance, leading to tumor progression and poor prognosis. Understanding this process provides insights into immune evasion strategies and offers potential targets for immunotherapy. For instance, restoring NK cell chemotaxis by inhibiting negative regulators could enhance the efficacy of adoptive NK cell therapies or immune checkpoint inhibitors. Moreover, dysregulation of this process may contribute to autoimmune or inflammatory diseases where excessive NK cell recruitment causes tissue damage. Therefore, studying GO:2000502 is essential for both cancer biology and immunology.
• Tumor immune evasion: Tumors can suppress NK cell chemotaxis to avoid immune attack, promoting growth and metastasis.
• Prognostic marker: IL-1R8 expression in DLBCL regulates NK cell recruitment and influences patient prognosis.
• Therapeutic target: Modulating negative regulators could enhance NK cell-based immunotherapies.
• Viral pathogenesis: HPV downregulates CXCL14 to suppress NK cell chemotaxis, aiding viral persistence.
• Inflammatory diseases: Excessive or insufficient NK cell recruitment contributes to tissue damage or impaired pathogen clearance.
• Drug development: Identifying small molecules or biologics that inhibit negative regulation may boost immune responses.
• Basic immunology: Elucidating signaling pathways that control NK cell migration advances understanding of innate immunity.
• Biomarker discovery: Genes like LMO7 and COL6A6 may serve as biomarkers for immune evasion.
• Personalized medicine: Patient stratification based on NK cell chemotaxis regulators could guide immunotherapy.
• Combination therapies: Targeting negative regulation alongside checkpoint inhibitors may yield synergistic effects.
What Happens During negative regulation of natural killer cell chemotaxis?
Chemokine Gradient Disruption
In simple terms: Tumors or infected cells can reduce the production of chemokines that attract NK cells, making it harder for NK cells to find them.
Negative regulation of NK cell chemotaxis often begins with alterations in the chemokine gradient. For example, human papillomavirus (HPV) downregulates CXCL14, a chemokine that attracts NK cells, through epigenetic mechanisms, thereby suppressing antitumor immune responses. Similarly, in pancreatic ductal adenocarcinoma, LMO7 promotes regulatory T cell differentiation and chemotaxis, which may indirectly reduce NK cell recruitment by altering the chemokine milieu. This disruption prevents NK cells from sensing and migrating toward the tumor site.
Receptor Desensitization and Signaling Inhibition
In simple terms: Even if chemokines are present, NK cells may become unresponsive due to changes in their receptors or intracellular signaling.
Negative regulation can also occur at the level of NK cell receptors or downstream signaling. Although specific mechanisms are not fully elucidated, studies on other immune cells suggest that chemokine receptor internalization or inhibition of G-protein coupled receptor signaling can dampen chemotaxis. In the context of NK cells, IL-1R8 expression in diffuse large B-cell lymphoma (DLBCL) regulates NK cell recruitment, potentially by modulating signaling pathways that control migration. Further research is needed to identify the exact molecular players.
Cellular Interference and Physical Barriers
In simple terms: Other cells, such as regulatory T cells or cancer-associated fibroblasts, can physically block or redirect NK cells away from targets.
The tumor microenvironment can create physical or cellular barriers that impede NK cell chemotaxis. For instance, LMO7-driven regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma may establish an immunosuppressive niche that excludes NK cells. Additionally, collagen type VI alpha 6 chain (COL6A6) has been implicated as a potential tumor suppressor in breast cancer with immune regulation perspectives, suggesting that extracellular matrix components can influence NK cell migration. These cellular and matrix interactions contribute to negative regulation.
Epigenetic and Transcriptional Control
In simple terms: Cells can turn off genes that produce chemokines or turn on genes that inhibit NK cell movement.
Epigenetic silencing of chemokine genes is a key mechanism. HPV suppresses antitumor immune responses through epigenetic downregulation of CXCL14, which reduces NK cell chemotaxis. Similarly, transcriptional regulators such as LMO7 can alter gene expression programs that affect immune cell trafficking. These epigenetic and transcriptional changes provide long-term suppression of NK cell recruitment.
Integration with Other Immune Evasion Mechanisms
In simple terms: Negative regulation of NK cell chemotaxis often works together with other immune escape tactics, like checkpoint activation.
Negative regulation of NK cell chemotaxis is not an isolated event; it integrates with broader immune evasion strategies. For example, a bispecific integrin α5β1/αv antibody reprogrammed the Myc-regulated basal phenotype of prostate cancer and enabled NK cell-mediated tumor elimination, indicating that overcoming negative regulation can restore NK cell function. Thus, understanding this process in the context of the tumor microenvironment is essential for designing effective immunotherapies.
Key Genes Involved in GO:2000502 negative regulation of natural killer cell chemotaxis
The following genes and proteins have been implicated in the regulation of NK cell chemotaxis or related immune evasion pathways, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LMO7 | Drives immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma | Potential target to restore NK cell recruitment |
| GNLY | Granulysin, a cytolytic protein with clinical relevance in immunity | May influence NK cell function and chemotaxis |
| IL1R8 | Regulates NK cell recruitment in DLBCL | Prognostic marker and therapeutic target |
| COL6A6 | Potential tumor suppressor in breast cancer with immune regulation perspective | May affect extracellular matrix and NK cell migration |
| CXCL10 | Chemokine that induces migration of adoptively transferred human NK cells toward solid tumors | Key attractant for NK cells; downregulation reduces chemotaxis |
| CXCL14 | Chemokine downregulated by HPV to suppress antitumor immunity | Epigenetic silencing reduces NK cell recruitment |
| CXCR3 | Receptor for CXCL10 on NK cells | Mediates chemotaxis; potential target for modulation |
| ITGA5 | Integrin α5, involved in prostate cancer phenotype and NK cell-mediated elimination | Targeting integrins may overcome negative regulation |
| ITGB1 | Integrin β1, partner of α5 | Involved in cell adhesion and migration |
| ITGAV | Integrin αv, part of bispecific antibody target | Modulates tumor microenvironment and NK cell function |
| MYC | Oncogene regulating basal phenotype in prostate cancer | Its reprogramming enables NK cell elimination |
| FOXP3 | Master regulator of regulatory T cells | Tregs can suppress NK cell chemotaxis indirectly |
| CCR5 | Chemokine receptor on NK cells | May mediate migration in inflammatory contexts |
| CCR7 | Chemokine receptor involved in lymphocyte trafficking | Potential role in NK cell homing |
| IFNG | Interferon gamma, produced by NK cells | Effector cytokine; its production depends on NK cell arrival |
| GZMB | Granzyme B, cytolytic effector | NK cell killing function after migration |
| PRF1 | Perforin, pore-forming protein | Essential for NK cell cytotoxicity |
How Is negative regulation of natural killer cell chemotaxis Regulated?
The negative regulation of NK cell chemotaxis is controlled by a complex network of signaling pathways. Chemokine production can be modulated by epigenetic mechanisms, as seen with HPV-mediated downregulation of CXCL14. Transcriptional regulators such as LMO7 influence regulatory T cell differentiation and chemotaxis, which in turn can suppress NK cell recruitment. In DLBCL, IL-1R8 expression regulates NK cell recruitment, likely through modulation of chemokine or cytokine signaling. Additionally, integrin signaling and the Myc-regulated basal phenotype in prostate cancer can impact NK cell-mediated tumor elimination, suggesting that oncogenic pathways can indirectly control NK cell chemotaxis. These regulatory layers provide multiple points for therapeutic intervention.
negative regulation of natural killer cell chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LMO7 | Pancreatic ductal adenocarcinoma immune evasion | CRISPR knockout in PDAC cell lines, co-culture with NK cells |
| IL1R8 | Diffuse large B-cell lymphoma prognosis | Knockout or overexpression in DLBCL cell lines, NK recruitment assays |
| CXCL14 | HPV-associated cancers | CRISPR activation or epigenetic editing in HPV+ cell lines |
| COL6A6 | Breast cancer tumor suppression | Knockout in breast cancer cells, NK chemotaxis assays |
| ITGA5/ITGB1 | Prostate cancer NK cell elimination | Bispecific antibody treatment, NK cytotoxicity assays |
Cancer Immune Evasion
Negative regulation of NK cell chemotaxis is a hallmark of cancer immune evasion. In pancreatic ductal adenocarcinoma, LMO7 drives immune evasion by promoting regulatory T cell differentiation and chemotaxis, which may exclude NK cells from the tumor microenvironment. In diffuse large B-cell lymphoma, IL-1R8 expression regulates NK cell recruitment and influences patient prognosis, with high expression potentially correlating with poor NK cell infiltration. Human papillomavirus downregulates CXCL14 to suppress antitumor immune responses, reducing NK cell chemotaxis and allowing viral persistence and tumor development. These examples highlight how cancers exploit this process to escape innate immunity.
Viral Infections
Viruses can manipulate NK cell chemotaxis to establish chronic infections. HPV epigenetically downregulates CXCL14, a chemokine that attracts NK cells, thereby suppressing antitumor immunity and aiding viral immune evasion. This mechanism may also apply to other viruses that alter chemokine networks. Understanding how viruses negatively regulate NK cell chemotaxis could lead to therapies that restore immune surveillance.
Inflammatory and Autoimmune Conditions
Dysregulated NK cell chemotaxis can contribute to inflammatory diseases. While negative regulation is often beneficial to prevent excessive tissue damage, inadequate regulation may lead to autoimmune reactions. Granulysin, a cytolytic protein, has clinical relevance in immunity and inflammation. However, direct evidence linking GO:2000502 to specific autoimmune diseases is limited and requires further investigation.
From negative regulation of natural killer cell chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of LMO7 restore NK cell chemotaxis in PDAC? | CRISPR knockout of LMO7 in PDAC cell lines, co-culture with NK cells |
| Does point mutation in IL1R8 affect NK cell recruitment? | CRISPR point mutation in DLBCL cell lines, chemotaxis assays |
| Can knock-in of CXCL14 reverse HPV-mediated immune evasion? | CRISPR knock-in of CXCL14 in HPV+ cells, NK migration assays |
| Does overexpression of COL6A6 enhance NK cell chemotaxis? | Overexpression of COL6A6 in breast cancer cells, NK recruitment assays |
| Can tagged knock-in of CXCR3 track receptor dynamics? | Tagged knock-in of CXCR3 in NK cells, live imaging |
| Does knockout of ITGA5 sensitize prostate cancer to NK cells? | CRISPR knockout of ITGA5 in prostate cancer cells, NK cytotoxicity assays |
How to Study the negative regulation of natural killer cell chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell migration assay | Number of migrated NK cells | Assess chemotaxis toward chemokines |
| RNA-seq | Gene expression changes | Identify altered chemokine or receptor genes |
| Proteomics | Protein levels and secretion | Discover factors regulating NK cell recruitment |
| Live-cell imaging | Real-time NK cell movement | Visualize chemotaxis in 3D models |
| CRISPR knockout | Loss-of-function effects | Determine causal role of candidate genes |
| CRISPR knock-in | Tagged or mutant protein expression | Track receptor localization or function |
| Overexpression | Gain-of-function effects | Test if a gene enhances negative regulation |
| Bioinformatics analysis | Pathway enrichment and networks | Identify novel regulators from omics data |
Chemotaxis Assays
Transwell migration assays are commonly used to measure NK cell chemotaxis. NK cells are placed in the upper chamber, and chemokines such as CXCL10 or CXCL14 are added to the lower chamber. The number of migrated cells is quantified. This method can be used to assess the effect of genetic modifications (e.g., knockout of LMO7) on NK cell recruitment.
RNA Sequencing and Transcriptomics
RNA-seq can identify changes in gene expression related to chemokine production or NK cell migration. For example, comparing tumor cells with or without LMO7 knockout can reveal altered chemokine profiles. Similarly, transcriptomic analysis of HPV-infected cells has shown downregulation of CXCL14.
Proteomics and Cytokine Profiling
Proteomic approaches, such as mass spectrometry or cytokine arrays, can measure secreted chemokines and cytokines in the tumor microenvironment. This helps identify factors that negatively regulate NK cell chemotaxis. For instance, IL-1R8 expression in DLBCL may alter cytokine secretion, affecting NK cell recruitment.
Imaging and Live-Cell Tracking
Intravital imaging or live-cell microscopy can visualize NK cell migration in real time within tissues. Tagged knock-in of chemokine receptors (e.g., CXCR3) with fluorescent proteins allows tracking of receptor dynamics and NK cell movement. This method provides spatial and temporal insights into negative regulation.
How CRISPR Can Be Used to Study GO:2000502 negative regulation of natural killer cell chemotaxis
Knockout
CRISPR knockout is used to delete genes suspected of negatively regulating NK cell chemotaxis. For example, knocking out LMO7 in pancreatic ductal adenocarcinoma cells can test whether it is required for immune evasion and reduced NK cell recruitment. Similarly, knockout of IL1R8 in DLBCL cells can reveal its role in NK cell recruitment. This approach provides definitive loss-of-function evidence.
Point Mutation
CRISPR point mutation introduces specific amino acid changes to dissect functional domains. For instance, mutating key residues in IL1R8 or its signaling partners could clarify how it regulates NK cell chemotaxis without completely abolishing protein expression. This is useful for separating structural from signaling functions.
Knock-in
CRISPR knock-in can insert tags (e.g., GFP) or restore expression of a gene. Tagged knock-in of CXCR3 in NK cells allows visualization of receptor trafficking during chemotaxis. Knock-in of CXCL14 in HPV-infected cells could test whether restoring its expression reverses the suppression of NK cell chemotaxis.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can drive high expression of candidate genes. Overexpressing COL6A6 in breast cancer cells can test whether it enhances or inhibits NK cell chemotaxis. This gain-of-function approach complements knockout studies.
How EDITGENE Supports negative regulation of natural killer cell chemotaxis Research
Researchers studying negative regulation of natural killer cell chemotaxis-related genes often need to determine whether a candidate gene is causally involved in suppressing NK cell migration. EDITGENE provides comprehensive CRISPR gene editing services to accelerate this research, from knockout to knock-in and overexpression models, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of natural killer cell chemotaxis research.
Frequently Asked Questions About negative regulation of natural killer cell chemotaxis
What is GO:2000502?
GO:2000502 is a Gene Ontology term for negative regulation of natural killer cell chemotaxis, describing any process that stops, prevents or reduces the directed migration of NK cells along chemical gradients.
What genes are involved in negative regulation of natural killer cell chemotaxis?
Genes such as LMO7, IL1R8, CXCL14, COL6A6, and CXCL10 have been implicated in regulating NK cell chemotaxis or related immune evasion pathways.
How do tumors suppress NK cell chemotaxis?
Tumors can downregulate chemokines like CXCL14, recruit regulatory T cells, or alter signaling pathways to prevent NK cells from reaching the tumor site.
What diseases are associated with negative regulation of NK cell chemotaxis?
Cancers such as pancreatic ductal adenocarcinoma, diffuse large B-cell lymphoma, and HPV-associated cancers, as well as certain viral infections, involve this process.
What experimental models are used to study GO:2000502?
Transwell migration assays, CRISPR knockout/knock-in cell lines, RNA-seq, proteomics, and live-cell imaging are commonly used.
Can CRISPR be used to study negative regulation of NK cell chemotaxis?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect gene function in NK cell chemotaxis.
What is the role of CXCL10 in NK cell chemotaxis?
CXCL10 induces migration of adoptively transferred human NK cells toward solid tumors, causing tumor regression in vivo.
How does HPV evade NK cells?
HPV epigenetically downregulates CXCL14, a chemokine that attracts NK cells, thereby suppressing antitumor immune responses.
What is the clinical significance of IL-1R8 in DLBCL?
IL-1R8 expression in DLBCL regulates NK cell recruitment and influences patient prognosis, making it a potential biomarker and therapeutic target.
What services does EDITGENE offer for studying this process?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services to study negative regulation of NK cell chemotaxis.
Conclusion
Negative regulation of natural killer cell chemotaxis (GO:2000502) is a vital mechanism in immune evasion and disease progression. Understanding the genes and pathways involved, such as LMO7, IL1R8, and CXCL14, offers opportunities for therapeutic intervention. By leveraging CRISPR-based models and advanced screening, researchers can uncover novel regulators and develop strategies to enhance NK cell-based immunotherapies. EDITGENE stands ready to support these efforts with tailored gene editing services.
References
- 1. Dai S et al.. 2025. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma.. Cell Death Differ 32(2):271-290 PMID: 39143228
- 2. Krensky AM et al.. 2009. Biology and clinical relevance of granulysin.. Tissue Antigens 73(3):193-8 PMID: 19254247
- 3. Yu M et al.. 2023. IL-1R8 expression in DLBCL regulates NK cell recruitment and influences patient prognosis.. Funct Integr Genomics 23(4):328 PMID: 37907630
- 4. Li JD et al.. 2025. The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective.. BMC Cancer 25(1):1363 PMID: 40846911
- 5. Wu LY et al.. 2022. Identification of vasospasm biomarkers for cerebral hemorrhage via bio-informatics analysis.. Ann Palliat Med 11(1):173-184 PMID: 35144409
- 6. Joshi R et al.. 2025. A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell-Mediated Tumor Elimination.. Mol Cancer Res 23(10):873-888 PMID: 40548863
- 7. Wennerberg E et al.. 2015. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.. Cancer Immunol Immunother 64(2):225-35 PMID: 25344904
- 8. Cicchini L et al.. 2016. Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14.. mBio 7(3) PMID: 27143385
